GlobeNewsWire
07 Dec 2025, 23:00 UTC · 49w ago
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
Impact · against what's priced in
SELLAS Life Sciences is a significant positive catalyst as Phase 2 data for SLS009 shows a 46% response rate and substantial survival improvement in a difficult-to-treat AML-MR population. The efficacy in high-risk ASXL1 and TP53 mutations, combined with a clean safety profile, strongly supports the drug's therapeutic potential.
- SLS+0.80
No priced-in read yet





